h37rv

n-acetylciprofloxacin (3-Quinolinecarboxylic acid, 7-(4-acetyl-1-piperazinyl)-1-cyclopropyl-6-fluoro-1) is inhibitor of H37Rv.

Anti-TB agent 1 is a potent and orally active anti-tuberculosis compound (MICs: < 2 nM against the Mtb strains H37Rv, rRMP, and rINH).

Urease Inhibitor 07 is an isosubstituted metalloproteinase inhibitor with potential activity against Mycobacterium tuberculosis strain H37Rv.

Thiacetazone (Diazam) is a thiosemicarbazone that thioacetazone treatment of pulmonary tuberculosis

sCNH240 (2-Fluoro-N-[3-(3-thienyl)-5-isoxazolyl]benzenesulfonamide) is a potential and selective Rv1625c Cya activator with good cell permeability and oral activity, IC90=1.24 μM in cholesterol-supplemented 7H12 medium against Mycobacterium tuberculosis (Mtb) H37Rv strain, and inhibition of CYP2C19, CYP2C9 and hERG channels.

TBA-354 is anti-tuberculous and active against Mycobacterium tuberculosis strain H37Rv.

BM635 is an MmpL3 inhibitor with outstanding anti-mycobacterial activity (MIC50: 0.12 μM against M. tuberculosis H37Rv).

BM635 hydrochloride is an MmpL3 inhibitor with outstanding anti-mycobacterial activity (MIC50: 0.12 μM against M. tuberculosis H37Rv).

BM635 mesylate is an MmpL3 inhibitor with outstanding anti-mycobacterial activity (MIC50: 0.12 μM against M. tuberculosis H37Rv).

MDRTB-IN-1 (5aα) is an antibiotic effective against Mycobacterium tuberculosis H37Rv, with a MIC90 of 10.5 μM.

NITD-349 is an inhibitor of MmpL3. It shows highly potent anti-mycobacterial activity with MIC50 of 23 nM against virulent Mycobacterium tuberculosis H37Rv.

VEGFR-2 InhA-IN-1, a dual inhibitor based on pyrazole, targets InhA and VEGFR, exhibiting both anti-tuberculosis and anti-angiogenic properties. It demonstrates effective antibacterial activity against the Mycobacterium tuberculosis H37Rv strain (MIC = 6.25 μg mL) and significantly suppresses VEGFR-2 activity (IC 50 = 15.27 nM).

ATP synthase inhibitor3 (compound PT6) is an orally active inhibitor targeting the F-ATP synthase of Mycobacterium tuberculosis (IC50=0.788 μM). It effectively inhibits the growth of the Mycobacterium tuberculosis H37Rv strain (ATCC-27294) in vitro, depleting intracellular ATP levels at an IC50 of 30 μM.

InhA-IN-8 (compound 6c) serves as an orally effective inhibitor of the Mycobacterium tuberculosis enzyme InhA (enoyl-ACP reductase). This compound demonstrates robust inhibitory activity against Mtb H37Rv, with a minimum inhibitory concentration (MIC) ranging from 0.5 to 1 μg mL. Additionally, InhA-IN-8 is utilized in studies involving acute tuberculosis models in mice.

DprE1-IN-11 (compound 3) is an orally active DprE1 inhibitor that exhibits antitubercular activity against both MTB H37Rv and MDR-MTB strains (MIC <0.029-0.095 μM).

HT1171 is a potent and selective inhibitor of the Mycobacterium tuberculosis proteasome. It exhibits strong antitubercular activity against Mycobacterium tuberculosis H37Rv, with a MIC90 of 2 μg mL and MIC of 4 μg mL. At a concentration of 100 μM, HT1171 shows an inhibition rate of 53.8% against normal human liver cells (L02). HT1171 is applicable in antituberculosis drug research.

Pks13-IN-1 (Compound 44) is an orally active inhibitor of Mycobacterium tuberculosis polyketide synthase 13 (Pks13). It inhibits the M. tuberculosis H37Rv strain with a minimum inhibitory concentration (MIC) of 0.07 μM. In mouse models, Pks13-IN-1 demonstrates antibacterial activity.

Pks13-IN-2 (Compound 43) is an orally active inhibitor of Pks13. It exhibits inhibitory activity against Mycobacterium tuberculosis H37Rv, with a MIC of 0.8-1.8 μM. Pks13-IN-2 demonstrates good metabolic stability in mouse liver microsomes and hepatocytes, making it suitable for tuberculosis research.

JNJ-2901 is an inhibitor of M. tuberculosis cytochrome bc1:aa3. It effectively reduces bacterial load in acute and chronic mouse infection models of M. tuberculosis H37Rv-ΔcydAB. JNJ-2901 is useful for tuberculosis (TB) research.

JSF-4898 is an orally bioactive inhibitor of Mycobacterium tuberculosis MenG enzyme. It exhibits a minimum inhibitory concentration (MIC) of 0.78 μM against Mycobacterium tuberculosis H37Rv. Additionally, JSF-4898 enhances the efficacy of rifampicin in a subacute infection model of Mycobacterium tuberculosis in mice.

Mycobacterium Tuberculosis-IN-8 (Compound 6g) is a selective inhibitor of Mycobacterium tuberculosis (MTB), with a MIC value of 6.25 µg/mL against MTB H37Rv. It demonstrates potent antitubercular activity by inhibiting mycolic acid biosynthesis, which is crucial for maintaining bacterial cell wall integrity. Mycobacterium Tuberculosis-IN-8 holds potential for research in antitubercular agents.

Antitubercular agent-42(19) is a selective inhibitor of fatty acyl-AMP ligase (FAAL), demonstrating a MIC90 of 1.4 µg/mL against M. tuberculosis H37Rv, and possesses antitubercular activity.

Antitubercular agent-44 (compound 21b) displays antitubercular activity with an H37Rv MIC of 0.06 μM and is orally active.

Anti-infective agent 8 (compound 9d) is an antibacterial compound with a minimum inhibitory concentration (MIC) of 0.5 μg/mL against Staphylococcus aureus and Mycobacterium tuberculosis H37Rv. Additionally, it possesses antibiofilm properties, significantly reducing the formation of Staphylococcus aureus biofilms.